On September 3rd, Senseonics announced that its implantable Eversense CGM will now be covered by two state Blue Cross Blue Shield insurance providers – Blue Cross Blue Shield of Massachusetts and Blue Cross of Idaho.
Senseonics has been steadily working to roll out its CGM since receiving FDA approval for the device in April 2018. In March 2019, the company announced the creation of a limited-time program to offer the CGM at a discount for qualifying patients who lacked insurance coverage for the device. In May 2019, the company announced that it found a distributor to make the Eversense CGM accessible through the Veterans Health Administration, which provides health care for roughly 9 million veterans of the U.S. Armed Forces.
With the Eversense CGM, a small sensor is implanted under the skin. Users then wear a smart transmitter over the implanted sensor, which syncs with other devices and can also provide alerts by vibrating.
The sensor is currently approved by the FDA for up to 90 days of wear. In June 2019, the FDA approved an expanded label that indicates that the device is safe for non-adjunctive use, meaning that wearers can make insulin dosing decisions without a confirming fingerstick.